Company intelligence / Profile preview

Xenocor

Monrovia, California, United States

Ownership: Private
Development stage: Other

Overview

Xencor develops next-generation antibody and protein therapeutics for cancer and serious diseases using its proprietary XmAb® protein engineering platform. It has a broad pipeline, with more than 20 programs in clinical development and three partnered medicines on the market. The company is headquartered in Southern California and is recognized as a pioneer in biotech innovation in the Los Angeles region.

Therapeutic areas: OncologyOther
Modalities: Monoclonal antibodyBispecific monoclonal antibodyFc-fusion protein
Industry: Biotech

Partnerships

Major pharmaceutical companies

Beyond the preview

Go deeper on Xenocor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xenocor.

Explore the full profile